Abstract

The purpose of the proposed studies is to develop the ability to design individualized treatment regimens for patients with acute myelocytic leukemia (AML). To this end data regarding the clinical characteristics of AML patients is being collected so that the ability of patients to survive intensive remission induction therapy can be estimated. Previously untreated patients are being treated with the standard cooperative group protocols while relapsed patients are being uniformly treated on common protocols. Pretherapy in vitro leukemic cell drug sensitivity studies and all cycle studies will be carried out to assess the usefulness of assays which would be potentially useful for predicting response. Similarly serial bone marrow examinations during therapy and measurements of plasma drug levels achieved during therapy will be carried out to facilitate development of the means to make an early assessment of response to therapy while therapy is being administered.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA028734-04S1
Application #
3556969
Study Section
(SRC)
Project Start
1980-09-01
Project End
1987-04-30
Budget Start
1985-08-01
Budget End
1987-04-30
Support Year
4
Fiscal Year
1986
Total Cost
Indirect Cost

  Institution

Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263

  Publications

Ueno, M; Yamada, S; Zako, M et al. (2001) Structural characterization of heparan sulfate and chondroitin sulfate of syndecan-1 purified from normal murine mammary gland epithelial cells. Common phosphorylation of xylose and differential sulfation of galactose in the protein linkage region tetrasa J Biol Chem 276:29134-40
Raza, A; Preisler, H; Lampkin, B et al. (1993) Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia. Am J Hematol 42:147-57
Yamagata, M; Saga, S; Kato, M et al. (1993) Selective distributions of proteoglycans and their ligands in pericellular matrix of cultured fibroblasts. Implications for their roles in cell-substratum adhesion. J Cell Sci 106 ( Pt 1):55-65
Raza, A; Preisler, H D; Browman, G P et al. (1993) Long-term outcome of patients with acute myelogenous leukemia: the role of maintenance therapy, consolidation therapy and the predictive value of two in vitro assays. Leuk Lymphoma 10:57-66
Raza, A; Gezer, S; Anderson, J et al. (1992) Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study. Exp Hematol 20:1194-200
Larson, R A; Day, R S; Azarnia, N et al. (1992) The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study. Br J Haematol 82:337-46
Raza, A; Yousuf, N; Abbas, A et al. (1992) High expression of transforming growth factor-beta long cell cycle times and a unique clustering of S-phase cells in patients with acute promyelocytic leukemia. Blood 79:1037-48
Khan, S P; Raza, A; Barcos, M et al. (1991) Cell cycle and clinical characteristics of patients with acute myeloid leukemia and myelodysplasia whose biopsies are reactive with anti-factor VIII antibody. A Leukemia Intergroup Study. Leuk Res 15:51-7
Raza, A; Preisler, H; Lampkin, B et al. (1991) Biological significance of cell cycle kinetics in 128 standard risk newly diagnosed patients with acute myelocytic leukemia. Br J Haematol 79:33-9
Preisler, H D; Larson, R A; Raza, A et al. (1991) The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failure. Br J Haematol 79:390-7

Showing the most recent 10 out of 40 publications